Timothy Walbert

Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc

Timothy Walbert

Timothy Walbert

Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc

Overview
Career Highlights

Horizon Therapeutics Plc
Horizon Therapeutics USA, Inc.
Horizon Pharma, Inc.

RelSci Relationships

2552

Number of Boards

22

Birthday

1967

Age

53

Relationships
RelSci Relationships are individuals Timothy Walbert likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Vice President, Chief Medical Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Managing Director at Essex Woodlands Management, Inc.

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Chief Financial Officer at BioQ Pharma, Inc.

Relationship likelihood: Strong

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Former President, US Operations at Eli Lilly & Company

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

Director & Founding Member at MATTER Chicago

Relationship likelihood: Strong

Executive Vice President, Chief Business Officer at Horizon Therapeutics USA, Inc.

Relationship likelihood: Strong

Vice President Finance at Recro Gainesville LLC

Relationship likelihood: Strong

Paths to Timothy Walbert
Potential Connections via
Relationship Science
You
Timothy Walbert
Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc
Education
BA in Business & Marketing

Founded in 1848, Muhlenberg is a highly selective, private, four-year liberal arts college. The College took its present name in 1867 from Henry Melchior Muhlenberg, patriarch of the Lutheran Church in the American Colonies. The College offers 40 majors in the humanities, fine arts, social sciences and natural sciences, in addition to strong pre-professional programs in such areas as pre-health, pre-law, pre-theology, business and education.

Career History
Chairman, President & Chief Executive Officer
2008 - Current

Horizon Therapeutics Plc is a biopharmaceutical company which is engaged in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. The company was founded in 2008 and is headquartered in Dublin, Ireland.

President, Chief Executive Officer, Chairman
Current

Horizon Pharma USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.

Chairman, President & Chief Executive Officer
2008 - Prior

Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.

Boards & Committees
Member, Board of Directors
2007 - 2009

IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Horizon Therapeutics Plc issued Ordinary Shares

Details Hidden

Horizon Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Timothy Walbert. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Timothy Walbert's profile does not indicate a business or promotional relationship of any kind between RelSci and Timothy Walbert.